{"schema_version":"secwatch.filing_event.v1","accession":"0001933414-23-000090","form_type":"8-K","ticker":"MLYS","cik":"0001933414","company_name":"Mineralys Therapeutics, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.419610+00:00","generated_at":"2026-06-08T05:44:52.051173+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Mineralys Therapeutics presents new leptin analysis from Target-HTN trial of lorundrostat","bullets":["Elevated BMI (>30 kg/m²) predicted enhanced systolic BP reduction: placebo-adjusted drops of 16.7 mmHg (50 mg) and 12.3 mmHg (100 mg).","New analysis shows increased serum leptin correlates with higher BMI, suggesting leptin as a biomarker for responsive patients.","Target-HTN results support transition to late-stage development; Advance-HTN pivotal trial enrolling, Launch-HTN expected H2 2023.","Data presented at AHA Scientific Sessions 2023 in Philadelphia."],"urls":{"canonical":"https://secwatch.observer/filing/0001933414-23-000090","json":"https://secwatch.observer/filing/0001933414-23-000090.json","markdown":"https://secwatch.observer/filing/0001933414-23-000090.md","text":"https://secwatch.observer/filing/0001933414-23-000090.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933414/000193341423000090/0001933414-23-000090-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933414/000193341423000090/mlys-20231111.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:44:52.051173+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}